ETX E-therapeutics Plc

TIDMETX

RNS Number : 2970O

e-Therapeutics plc

31 January 2023

E-THERAPEUTICS PLC

("e-therapeutics" or the "Company")

Total Voting Rights

London, UK, 31 January 2023 - e-therapeutics plc (AIM: ETX), the drug discovery company, announces that in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company has 582,159,332 ordinary shares of 0.1 pence each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 582,159,332.

The above figure of 582,159,332 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company.

For further information, please contact:

 
    e-therapeutics plc 
    Ali Mortazavi, CEO                             Tel: +44 (0)1993 883 
     James Chandler, VP IR & Communications         125 
                                                    www.etherapeutics.co.uk 
------------------------------------------------  ------------------------- 
 
     SP Angel Corporate Finance LLP                Tel: +44(0)20 3470 0470 
    Nominated Adviser and Broker 
    Matthew Johnson/Harry Davies-Ball (Corporate 
     Finance) 
    Vadim Alexandre/Rob Rees (Corporate Broking) 
------------------------------------------------  ------------------------- 
 

About e-therapeutics plc

About e-therapeutics plc

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.

ETX's proprietary Computational Biology Platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery that explicitly considers the true complexity of biology and makes more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data and information resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by ETX's Computational Biology Platform. The focus on hepatocytes offers the opportunity to work across a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates in several therapeutic areas including haematology, cardiovascular disease and non-alcoholic steatohepatitis ("NASH"). ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRZZGFMDGFGFZM

(END) Dow Jones Newswires

January 31, 2023 02:00 ET (07:00 GMT)

E-therapeutics (LSE:ETX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

E-therapeutics (LSE:ETX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025